Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost Punctal Plug Delivery System (L-PPDS) in Glaucoma/OH
NCT00967811Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2009
- Primary completion
- May 2010
- Countries
- 1
- Sponsor
- Mati Therapeutics
- Modality
- Orthosteric Ligands
- Drugs
- latanoprost
- Conditions
- ocular hypertensionopen-angle glaucoma (OAG)
01
Overview
Phase 2, randomised, open-label trial of latanoprost in ocular hypertension and open-angle glaucoma (OAG) (2 arms), sponsored by Mati Therapeutics. Primary endpoint: Intraocular Pressure change from baseline at 12 weeks. Started Aug 2009; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Formulation E1
Formulation E1 of Latanoprost-PPDS
Formulation E2
Formulation E2 of Latanoprost-PPDS
03
Who it enrols
Adult patients with ocular hypertension or open-angle glaucoma, BCVA 20/100 or better, excluding those with contact lenses, uncontrolled medical conditions, or requiring chronic ocular topical medications.
04
Endpoints
Primary
Intraocular Pressure change from baseline
Beyond the preview
Go deeper on NCT00967811.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00967811.